Back to top

biotechnology: Archive

Zacks Equity Research

Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?

Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.

ILMNNegative Net Change

Zacks Equity Research

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.

ARCTPositive Net Change STRONegative Net Change FULCNegative Net Change BVSNegative Net Change

Zacks Equity Research

Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition

Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.

REGNNegative Net Change ALNYNegative Net Change NVSPositive Net Change RHHBYPositive Net Change

Zacks Equity Research

Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug

Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.

LLYNegative Net Change BAYRYNegative Net Change EXELNegative Net Change

Zacks Equity Research

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.

ARCTPositive Net Change GLPGNegative Net Change FULCNegative Net Change BVSNegative Net Change

Madhurima Das

Energy Fuels (UUUU) Enters Medical Isotope Market: Buy the Stock?

Energy Fuels (UUUU) buys RadTran to leverage know-how to produce medical isotopes used in cancer treatments. Let us find out whether this can boost the stock.

CCJPositive Net Change UUUUPositive Net Change UECPositive Net Change

Zacks Equity Research

Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review

Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.

AZNNegative Net Change BMYPositive Net Change ILMNNegative Net Change ARCTPositive Net Change

Zacks Equity Research

Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug

Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.

RDYPositive Net Change ILMNNegative Net Change ARCTPositive Net Change HLNPositive Net Change

Zacks Equity Research

Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe

Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.

ILMNNegative Net Change NBIXNegative Net Change ARCTPositive Net Change XENENegative Net Change

Ekta Bagri

Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News

Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.

REGNNegative Net Change GILDPositive Net Change INCYNegative Net Change LQDANegative Net Change

Zacks Equity Research

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug

Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.

REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change

Zacks Equity Research

Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated

Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.

BMYPositive Net Change BMRNNegative Net Change KRYSNegative Net Change TSVTNegative Net Change

Zacks Equity Research

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.

SNYNegative Net Change BMYPositive Net Change KRYSNegative Net Change KYMRPositive Net Change

Andrew Rocco

Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed

Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.

NVONegative Net Change LLYNegative Net Change SBUXNegative Net Change MCDPositive Net Change SHAKNegative Net Change

Zacks Equity Research

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.

ILMNNegative Net Change ARCTPositive Net Change ABBVPositive Net Change GMABNegative Net Change

Zacks Equity Research

Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions

Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions have been highlighted in this Investment Ideas article.

APDNNegative Net Change EBSNegative Net Change GOVXNegative Net Change VRAXNegative Net Change

Ekta Bagri

ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?

The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.

GRFSNegative Net Change ADMAPositive Net Change TAKPositive Net Change

Andrew Rocco

WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch

Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.

APDNNegative Net Change TNXPNegative Net Change EBSNegative Net Change GOVXNegative Net Change VRAXNegative Net Change

Zacks Equity Research

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.

ILMNNegative Net Change ARCTPositive Net Change ANTXNegative Net Change FULCNegative Net Change